Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Pharmacology & Therapeutics Wiley

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection

Loading next page...
 
/lp/wiley/exposure-response-analyses-of-upadacitinib-efficacy-in-phase-ii-trials-VhNmJ2Vxob

References (37)

Publisher
Wiley
Copyright
© 2019 American Society for Clinical Pharmacology and Therapeutics
ISSN
0009-9236
eISSN
1532-6535
DOI
10.1002/cpt.1543
Publisher site
See Article on Publisher Site

Abstract

Journal

Clinical Pharmacology & TherapeuticsWiley

Published: Dec 1, 2019

There are no references for this article.